Antibody-Based Treatment of Acute Myeloid Leukemia

Phillip M. Garfin; Eric J. Feldman

doi:10.1007/s11899-016-0349-7

Antibody-Based Treatment of Acute Myeloid Leukemia

Phillip M. Garfin, Eric J. Feldman

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

While antibody-based therapies have emerged as clinically effective approaches for several hematologic and solid malignancies, they have not played a significant role to date in the treatment of acute myeloid leukemia (AML). More recently, improvements in antibody-drug conjugate technology, bispecific antibodies, as well as identification of novel AML antigens have re-invigorated enthusiasm for antibody-based therapies for AML. This review describes experiences with former and existing antibody-based therapies for AML, including unconjugated antibodies, antibody-drug conjugates (ADCs), radio-labelled antibodies, and immune-engaging antibodies, and discusses the promise and challenges associated with each.

Original language	English (US)
Pages (from-to)	545-552
Number of pages	8
Journal	Current Hematologic Malignancy Reports
Volume	11
Issue number	6
DOIs	https://doi.org/10.1007/s11899-016-0349-7
State	Published - Dec 1 2016
Externally published	Yes

Keywords

Acute myeloid leukemia
Antibody therapy
CD123
CD33
Immunotherapy

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11899-016-0349-7

Cite this

@article{089fe2261a3e4d86a513d45d29db5ff2,

title = "Antibody-Based Treatment of Acute Myeloid Leukemia",

abstract = "While antibody-based therapies have emerged as clinically effective approaches for several hematologic and solid malignancies, they have not played a significant role to date in the treatment of acute myeloid leukemia (AML). More recently, improvements in antibody-drug conjugate technology, bispecific antibodies, as well as identification of novel AML antigens have re-invigorated enthusiasm for antibody-based therapies for AML. This review describes experiences with former and existing antibody-based therapies for AML, including unconjugated antibodies, antibody-drug conjugates (ADCs), radio-labelled antibodies, and immune-engaging antibodies, and discusses the promise and challenges associated with each.",

keywords = "Acute myeloid leukemia, Antibody therapy, CD123, CD33, Immunotherapy",

author = "Garfin, {Phillip M.} and Feldman, {Eric J.}",

note = "Publisher Copyright: {\textcopyright} 2016, Springer Science+Business Media New York.",

year = "2016",

month = dec,

day = "1",

doi = "10.1007/s11899-016-0349-7",

language = "English (US)",

volume = "11",

pages = "545--552",

journal = "Current Hematologic Malignancy Reports",

issn = "1558-8211",

publisher = "Springer Science + Business Media",

number = "6",

}

TY - JOUR

T1 - Antibody-Based Treatment of Acute Myeloid Leukemia

AU - Garfin, Phillip M.

AU - Feldman, Eric J.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - While antibody-based therapies have emerged as clinically effective approaches for several hematologic and solid malignancies, they have not played a significant role to date in the treatment of acute myeloid leukemia (AML). More recently, improvements in antibody-drug conjugate technology, bispecific antibodies, as well as identification of novel AML antigens have re-invigorated enthusiasm for antibody-based therapies for AML. This review describes experiences with former and existing antibody-based therapies for AML, including unconjugated antibodies, antibody-drug conjugates (ADCs), radio-labelled antibodies, and immune-engaging antibodies, and discusses the promise and challenges associated with each.

AB - While antibody-based therapies have emerged as clinically effective approaches for several hematologic and solid malignancies, they have not played a significant role to date in the treatment of acute myeloid leukemia (AML). More recently, improvements in antibody-drug conjugate technology, bispecific antibodies, as well as identification of novel AML antigens have re-invigorated enthusiasm for antibody-based therapies for AML. This review describes experiences with former and existing antibody-based therapies for AML, including unconjugated antibodies, antibody-drug conjugates (ADCs), radio-labelled antibodies, and immune-engaging antibodies, and discusses the promise and challenges associated with each.

KW - Acute myeloid leukemia

KW - Antibody therapy

KW - CD123

KW - CD33

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84991096980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991096980&partnerID=8YFLogxK

U2 - 10.1007/s11899-016-0349-7

DO - 10.1007/s11899-016-0349-7

M3 - Review article

C2 - 27734262

AN - SCOPUS:84991096980

SN - 1558-8211

VL - 11

SP - 545

EP - 552

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

IS - 6

ER -

Antibody-Based Treatment of Acute Myeloid Leukemia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this